سعر ريباتوكسابان 20مجم 30 قرص 2026

Repatoxaban 20 mg 30 tabs: rivaroxaban 20 mg oral tablets (30 tablets), a direct factor Xa inhibitor; listed in Egypt under Horus for Pharmaceutical Products > Eva Pharma.

• Reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillationPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Treatment of DVT and PEPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Bleeding is the most common adverse reaction.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Active pathological bleeding.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Severe hypersensitivity reaction to rivaroxaban (e.g. anaphylaxis).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: premature discontinuation increases the risk of thrombotic events; consider alternative anticoagulant coverage.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning: epidural or spinal hematoma with neuraxial anesthesia or spinal puncture, which may cause permanent paralysis.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Increased risk of bleeding, including serious or fatal bleeding; risk increased by other drugs affecting hemostasis.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Combined P-gp and strong CYP3A inhibitors (e.g. ketoconazole, ritonavir)Avoid: increase rivaroxaban exposure and bleeding risk.DailyMed (U.S. National Library of Medicine)
• Combined P-gp and strong CYP3A inducers (e.g. carbamazepine, phenytoin, rifampin, St John's wort)Avoid: decrease exposure and may increase thromboembolic risk.DailyMed (U.S. National Library of Medicine)
• Anticoagulants, aspirin, P2Y12 inhibitors, NSAIDsIncrease bleeding risk; avoid other anticoagulants unless benefit outweighs risk.DailyMed (U.S. National Library of Medicine)

• Limited data are insufficient to inform drug-associated risk; use with caution because of potential pregnancy-related hemorrhage and/or emergent delivery; anticoagulant effect cannot be reliably monitored with standard tests.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Rivaroxaban is detected in human milk; effects on the breastfed child are unknown; weigh benefits of breastfeeding against maternal need.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Rivaroxaban: Selective direct inhibitor of factor Xa, reducing thrombin generation.